Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CLL 2022 | Genomic testing in CLL

Richard Rosenquist • 22 Mar 2022
ESH CLL 2022
Chronic Lymphocytic Leukemia Leukemia

Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, highlights the importance of genomic testing in chronic lymphocytic leukemia (CLL), drawing focus on fluorescence in situ hybridization (FISH) analysis, TP53 mutation screening, and testing of immunoglobin heavy chain gene (IgHV) mutational status. Dr Rosenquist then discusses how these genomic tests are an important part of treatment decision making and allow clinicians to better understand patient outcome in CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Disclosures

Received honoraria from AbbVie, AstraZeneca, Illumina, Janssen, and Roche

More from Richard Rosenquist

1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022
1:31
Using genomics to better understand the pathogenesis of CLL & for early disease diagnosis
Richard Rosenquist • 7 Oct 2022
1:38
The importance of TP53 in CLL
Richard Rosenquist • 7 Oct 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals